FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.863 USD
-0.0773 (-8.96%)
Historical Prices
From:
To:
About
ceo
Mr. Ilan Hadar M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://silexion.comexchange
NASDAQ
Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem,...
CIK
0002022416
ISIN
KYG1281K1067
CUSIP
N/A
Address
The Goldyne Savad Institute of...
Phone
972 2 674 3430
Country
IL
Employee
N/A
IPO Date
Aug 16, 2024
Financial Statement
Earnings
SLXN Financial Summary
CIK
0002022416
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
KYG1281K1067
Country
IL
Price
0.86
Beta
0.06
Volume Avg.
14.06M
Market Cap
7.5M
Shares
-
52-Week
0.207-13.558
DCF
-0.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://silexion.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SLXN News
It looks like there's no news available.
